ArticleEFSA journal. European Food Safety Authority2026
Assessment of the 2025 post-market monitoring report of genetically modified oilseed rape 73496.
Article in EFSA journal. European Food Safety Authority, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following a request from the European Commission, the European Food Safety Authority (EFSA) analysed the 2025 post-market monitoring (PMM) report of genetically modified oilseed rape (OSR) 73496 and the additional information provided during the assessment. EFSA concluded that the assumptions for consumption and for the intended uses considered during the pre-market risk assessment (human and animal dietary exposure) remain valid. The authorisation holder did not provide consumption data for humans and animals of OSR 73496 and of products derived from OSR 73496 as requested in the authorisation. However, EFSA concluded that the methodology used and the information provided are sufficient to conclude that the conditions considered during the pre-market risk assessment are still applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.